Searchable abstracts of presentations at key conferences in endocrinology

ea0077hdi1.1 | How do I. . .? 1 | SFEBES2021

Dr Claire Higham

Higham Claire

This talk will cover the currently available evidence describing the endocrine and metabolic consequences of radiotherapy treatment to the hypothalamus and pituitary. A practical approach to surveillance, diagnosis and management of these consequences in childhood and adult cancer survivors will be provided....

ea0050cmw1.3 | Workshop 1: Collateral damage of cancer treatment | SFEBES2017

Bone health in cancer survivors

Higham Claire

Cancer and treatments for cancer can have a significant impact on bone health in both children and adults. There are emerging data that bone mineral density is often reduced in survivors of childhood cancers and survivors of both solid tumours and haematological malignancies in adults. Fracture rates in childhood cancer survivors have not been shown to be increased. Older adult cancer survivors, particularly those treated with aromatase inhibitors and androgen deprivation ther...

ea0050cmw1.3 | Workshop 1: Collateral damage of cancer treatment | SFEBES2017

Bone health in cancer survivors

Higham Claire

Cancer and treatments for cancer can have a significant impact on bone health in both children and adults. There are emerging data that bone mineral density is often reduced in survivors of childhood cancers and survivors of both solid tumours and haematological malignancies in adults. Fracture rates in childhood cancer survivors have not been shown to be increased. Older adult cancer survivors, particularly those treated with aromatase inhibitors and androgen deprivation ther...

ea0094p32 | Bone and Calcium | SFEBES2023

Review of current guidelines on fracture risk recommendations in patients on hormonal therapies for Breast Cancer

Busch Sophia , Higham Claire

Introduction: Women prescribed hormonal therapies for breast cancer (eg Aromatase Inhibitors (AI) and ovarian suppression therapy (OST)) are at increased risk of fracture and monitoring of Bone Mineral Density (BMD) is needed. Recommendations for BMD monitoring and treatment interval thresholds differ between guidelines which has implications for management. We compared the outcomes from the application of 3 commonly used guidelines for bone health in women wi...

ea0044p242 | Thyroid | SFEBES2016

Occupational disability and access to psychological tools in thyroid eye disease

Kim Jennifer , Cook Anne , Higham Claire

Purpose: To evaluate the impact of thyroid eye disease (TED) on occupational disability and access to psychological input. Previous European studies have demonstrated a negative effect of TED on occupation but there are no similar UK studies.Methods: 102 outpatients under the age of 75 were identified for participation from a joint thyroid eye clinic at a tertiary centre. 42 completed a standardised fixed-choice questionnaire about occupational disabilit...

ea0041gp164 | Pituitary - Clinical (1) | ECE2016

Ipilimumab-induced hypophysitis in melanoma patients: a single centre experience

Kumar Mohit , Bowyer Samantha , Lorigan Paul , Higham Claire , Trainer Peter

Ipilimumab, a monoclonal antibody against CTLA-4, is licenced for the treatment of metastatic melanoma (dose of 3 mg/kg for four cycles intravenously). It can cause immune-related adverse reactions (IRAEs) in multiple organs, with hypophysitis the most common endocrine IRAE. We carried out a retrospective analysis of 171 ipilimumab-treated patients in one centre for endocrinopathies.Results: Nine cases (six female, mean age 64 years, range 42–76) of...

ea0037ep636 | Obesity and cardiovascular endocrinology | ECE2015

The use of intermittent 7.5 mg tolvaptan on an out-patient basis for SIADH: a retrospective audit from a tertiary cancer hospital

Kumar Mohit , Pichaipillai Lakshminarayanan , Trainer Peter , Higham Claire

Tolvaptan (a V2 receptor antagonist) is licensed for correction of hyponatraemia in patients with SIADH at an initial dose of 15 mg od. Data in oncology patients with SIADH suggest 7.5 mg can safely and effectively increase sodium levels where 15 mg can on occasion lead to too rapid a correction. Recommendations suggest a repeat sodium taken at 4–6 h. We retrospectively assessed the safety and efficacy of intermittent out-patient dosing with 7.5 mg tolv...

ea0037ep1236 | Clinical Cases–Pituitary/Adrenal | ECE2015

Accelerated sarcopenia as an initial manifestation of Cushing's disease

Pichaipillai Lakshminarayanan , Kumar Mohit , Pathmanathan Sivatharshya , Tiong Denise , Higham Claire

Introduction: Cushing’s syndrome usually presents with a phenotype including central obesity, striae, hypertension and diabetes. We report a case of Cushing’s syndrome presenting in an atypical manner.Case: A 73 year old lady was referred to neurology with a year’s history of progressive limb wasting, weakness and recurrent falls. The neurology team diagnosed accelerated sarcopenia. Investigations included CK (normal), EMG (suggested myopa...

ea0034p89 | Clinical practice/governance and case reports | SFEBES2014

Low dose tolvpatan (7.5 mg) is effective in the management of SIADH in oncology patients (results from a retrospective audit at The Christie Hospital and Wythenshawe Pulmonary Oncology Unit)

King Jennifer , Kyriacou Angelos , Issa Basil , Taylor Paul , Higham Claire

Tolvaptan (a selective V2 receptor antagonist) is licensed for the inpatient management of SIADH induced hyponatraemia, a common complication in patients with malignancy. Licensed daily doses start at 15 mg but there is evidence that some patients have a rise in serum sodium (Na) of >12 mmol/l per 24 h in response to this. Lower initial doses (7.5 mg) may therefore be appropriate1,2.Methods: A retrospective case note audit was performed. T...

ea0026p301 | Pituitary | ECE2011

Patients with active acromegaly (AA) have less hepatic triglyceride than normal subjects using proton magnetic resonance spectroscopy (1H MRS)

McGlynn Stephen , Morris Tim , Higham Claire , Williams Steve , Trainer Peter

A decrease in insulin sensitivity (IS) is associated with increasing visceral adiposity. An inverse correlation has been demonstrated between Intramyo-(IMTG) and intrahepatocellular triglyceride (HCTG) concentrations and IS. Patients with AA have reduced IS but IMTG and HCTG content has not been studied.Eight patients with AA (IGF-I >ULN, median 1.83×ULN (range1.16–4.38) ((6 M), median age 39.5 (range 23–66) years, median BMI 30.6(23.5...